periodo perioperatorio, anticoagulantes, warfarina, heparina de bajo-peso-molecular, Perioperative care, anticoagulants, warfarin, low-molecular-weight heparin,

1. Bevan F, Brookes M, Colebrook R et al. The assumptions used in estimating a benchmark rate of population requiring anticoagulation therapy per year. National institute for Health and Clinical Excellence [internet]; 2010. Disponible en: http://www.nice.org.uk/usingguidance/commissioningguides/anticoagulationtherapyservice/popbench.jsp.
2. Friberg J, Gislason GH, Gadsbøll N et al. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Intern Med. 2006 Feb;259(2):173-8.
3. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003 Apr 28;163(8):901-8. Review.
4. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am. 2001 Sep;85(5):1277-310, viii. Review.
5. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003 Dec 2;139(11):893-900.
6. Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009 Jan;40(1):235-40. Epub 2008 Aug 28.
7. White RH, Kaatz S, Douketis J et al. Comparison of the 30-day incidence of ischemic stroke and bleeding after major surgery in patients with or without atrial fibrillation (AF). J Thromb Haemost 2007;5(supl 1):O-M-035.
8. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):299S-339S.
9. Spyropoulos AC, Douketis JD. Guidelines for antithrombotic therapy: periprocedural management of antithrombotic therapy and use of bridging anticoagulation. Int Angiol. 2008 Aug;27(4):333-43.
10. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 Sep 23;52(13):e1-142.
11. Spyropoulos AC. To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. J Thromb Thrombolysis. 2010 Feb;29(2):192-8.
12. Jaff MR. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to “bridge” patients instead of intravenous unfractionated heparin? Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S17-
21. Review. 13. Douketis JD, Bakhsh E. Perioperative management of antithrombotic therapy. Pol Arch Med Wewn. 2008 Apr;118(4):201-8. Review.
14. O’Donnell M, Kearon C. Perioperative management of oral anticoagulation. Cardiol Clin. 2008 May;26(2):299-309, viii. Review.
15. Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg. 2008 Dec;95(12):1437-48. Review.
16. Du Breuil AL, Umland EM. Outpatient management of anticoagulation
therapy. Am Fam Physician. 2007 Apr 1;75(7):1031-42. Review
17. Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis. 2006 Feb;21(1):85-9. Review.
18. Ickx B, Motte S. Perioperative management of oral anticoagulation. Transfusion Alternatives in Transfusion Medicine. 2006 Sep;8(3):143-50.
19. O’Donnell M, Kearon C. Perioperative management of oral anticoagulation. Clin Geriatr Med. 2006 Feb;22(1):199-213, xi. Review.
20. Mannucci C, Douketis JD. The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians. Intern Emerg Med. 2006;1(2):96-104. Review.
21. Jafri SM, Mehta TP. Periprocedural management of anticoagulation in patients on extended warfarin therapy. Semin Thromb Hemost. 2004 Dec;30(6):657-64.
22. Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011 May 12;117(19):5044-9. Epub 2011 Mar 17.
23. Iqbal CW, Cima RR, Pemberton JH. Bleeding and thromboembolic outcomes for patients on oral anticoagulation undergoing elective colon and rectal abdominal operations. J Gastrointest Surg.
2011 Nov;15(11):2016-22. Epub 2011 Jul 1.
24. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004 Jun 28;164(12):1319-26.
25. Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. J Am Dent Assoc. 2003 Nov;134(11):1492-7. Review.
26. Bacci C, Maglione M, Favero L et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study. Thromb Haemost. 2010 Nov;104(5):972-5. Epub 2010 Aug 30.
27. Al-Mubarak S, Al-Ali N, Abou-Rass M et al. Evaluation of dental extractions, suturing and INR on postoperative bleeding of patients maintained on oral anticoagulant therapy. Br Dent J. 2007 Oct 13;203(7):E15.
28. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg. 2001 Dec;30(6):518-21.
29. Ramli R, Abdul Rahman R. Minor oral surgery in anticoagulated patients: local measures alone are sufficient for haemostasis. Singapore Dent J. 2005 Dec;27(1):13-6.
30. Evans IL, Sayers MS, Gibbons AJ et al. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. Br J Oral Maxillofac Surg. 2002 Jun;40(3):248-52.
31. Eisen GM, Baron TH, Dominitz JA et al. American Society for Gastrointestinal Endoscopy. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002 Jun;55(7):775-9.
32. Parras FA. Clinical practice guidelines for managing coagulation in patients undergoing endoscopic procedures. Rev Esp Enferm Dig. 2010 Feb;102(2):124-38. Review.
33. Székely H, Tulassay Z. [Anticoagulation and antiplatelet therapy, and gastrointestinal endoscopy]. Orv Hetil. 2009 Mar 22;150(12):541-8. Review. Hungarian.
34. Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol. 2009 Dec;104(12):3085-97.
35. Hirschman DR, Morby LJ. A study of the safety of continued anticoagulation for cataract surgery patients. Nurs Forum. 2006 Jan-Mar;41(1):30-7.
36. Katz J, Feldman MA, Bass EB, Lubomski LH et al. Study of medical testing for cataract surgery team: risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology. 2003 Sep;110(9):1784-8.
37. McCormack P, Simcock PR, Tullo AB. Management of the anticoagulated patient for ophthalmic surgery. Eye (Lond). 1993;7(Pt 6):749-50.
38. Kallio H, Paloheimo M, Maunuksela EL, Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth. 2000 Nov;85(5):708-11.
39. Syed S, Adams BB, Liao W, Pipitone M, Gloster H. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol. 2004 Dec;51(6):955-7.
40. Bassas P, Bartralot R, García-Patos V. Anticoagulation and antiplatelet therapy in dermatology. Actas Dermosifiliogr. 2009 Jan-Feb;100(1):7-16. Review. Spanish.
41. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg. 2001 Aug;27(8):756-8.
42. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010 Jan-Feb;35(1):64-101.
43. Jones HU, Muhlestein JB, Jones KW, Bair TL et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after openheart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation. 2002 Sep 24;106(12 Supl 1):119-22.
44. Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. Neurosurgery. 1999 Oct;45(4):838-47.
45. Patterson BM, Marchand R, Ranawat C. Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg Am. 1989 Sep;71(8):1130-4.
46. Nielsen JD, Gram J, Holm-Nielsen A, Fabrin K, Jespersen J. Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis. Br J Urol. 1997 Dec;80(6):889-93.
47. Sorbi D, Norton I, Conio M et al. Postpolypectomy lower GI bleeding: descriptive analysis. Gastrointest Endosc. 2000 Jun;51(6):690-6.
48. Ihezue CU, Smart J, Dewbury KC et al. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol. 2005 Apr;60(4):459-63; discussion 457-8.
49. Wiegand UK, LeJeune D, Boguschewski F et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest. 2004 Oct;126(4):1177-86.
50. Couillard P, Poppe AY, Coutts SB. Predicting recurrent stroke after minor stroke and transient ischemic attack. Expert Rev Cardiovasc Ther. 2009 Oct;7(10):1273-81.
51. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.
52. Camm AJ, Kirchhof P, Lip GY, Schotten U et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429.
53. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001 Jan;119(1 Supl):220S-7S.
54. Salem DN, Stein PD, Al-Ahmad A, Bussey HI et al. Antithrombotic therapy in valvular heart disease native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Supl):457S-82S.
55. Shapira Y, Vaturi M, Sagie A. Anticoagulant management of patients with mechanical prosthetic valves undergoing non-cardiac surgery: indications and unresolved issues. J Heart Valve Dis. 2001 May;10(3):380-7.
56. Salem DN, O’Gara PT, Madias C, Pauker SG; American College of Chest Physicians. Valvular and structural heart disease: ACCP evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6 Suppl):593S-629S.
57. Heit JA, Mohr DN, Silverstein MD, Petterson TM et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000 Mar 27;160(6):761-8.
58. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005 Mar 26-Apr 1;365(9465):1163-74.
59. White RH. The epidemiology of venous thromboembolism. Circulation. 2003 Jun 17;107(23 Supl 1):I4-8.
60. Büller HR, Agnelli G, Hull RD, Hyers TM et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Supl):401S-28S.
61. Douketis JD, Kearon C, Bates S et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998 Feb 11;279(6):458-62.
62. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997 May 22;336(21):1506-11.
63. Martinell J, Jiménez A, Rábago G et al. Mechanical cardiac valve thrombosis. Is thrombectomy justified? Circulation. 1991 Nov;84(5 Supl):III70-5.
64. Longstreth WT Jr, Bernick C, Fitzpatrick A et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology. 2001 Feb 13;56(3):368-75.
65. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006 Mar;22(3):471-81.
66. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996 Feb;92(2):479-85.
67. Dunn AS, Wisnivesky J, Ho W, Moore C et al. Perioperative management of patients on oral anticoagulants: a decision analysis. Med Decis Making. 2005 Jul-Aug;25(4):387-97.
68. Heit JA. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombolysis. 2001 Sep;12(1):81-7.
69. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 2005 Jul;19(4):179-202.
70. Van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010;(9):CD001100.
71. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecularweight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000 Jan;83(1):14-9.
72. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000 Apr 8;355(9211):1205-10.
73. Bath PM, Lindenstrom E, Boysen G, De Deyn P et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001 Sep 1;358(9283):702-10.
74. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke. 2000 Jul;31(7):1770-8.
75. Kalafut MA, Gandhi R, Kidwell CS, Saver JL. Safety and cost of low-molecularweight heparin as bridging anticoagulant therapy in subacute cerebral ischemia. Stroke. 2000 Nov;31(11):2563-8.
76. Amadeus Investigators, Booster MG, Bouthier J, Büller HR, Cohen AT, Crijns H et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008 Jan 26;371(9609):315-21.
77. Shapira Y, Sagie A, Battler A. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves. Clin Cardiol. 2002 Jul;25(7):323-7. Review.
78. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007 Nov;5(11):2211-8.
79. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J. 1978 Aug;96(2):163-5.
80. Ferreira I, Dos L, Tornos P, Nicolau I et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 2003 May;89(5):527-30.
81. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis. 2005 Aug;20(1):11-6.
82. Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis. 2007 May;16(3):285-92.
83. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999 Aug 15;84(4):478-80.
84. Tinmouth AH, Morrow BH, Cruickshank MK et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001 Jun;35(6):669-74.
85. Constans M, Santamaria A, Mateo J, Pujol N, Souto JC et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract. 2007 Feb;61(2):212-7.
86. Galla JM, Fuhs BE. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery. J Am Coll Cardiol 2000;35:531A
87. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004 May;125(5):1642-50.
88. Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J et al. Clinical outcomes with unfractionated heparin or low-molecularweight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006 Jun;4(6):1246-52.
89. Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol. 2008 Oct 1;102(7):883-9.
90. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005 Sep;94(3):528-31.
91. O‘Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I et al. Brief communication: Preoperative anticoagulant activity after bridging lowmolecular-weight heparin for temporaryinterruption of warfarin. Ann Intern Med. 2007 Feb 6;146(3):184-7.
92. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic - pharmacodynamic considerations. Clin Pharmacokinet. 1996 Apr;30(4):300-13.
93. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995 Jan 1;122(1):40-2.
94. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA. 1978 Feb 20;239(8):738-9.
95. Ansell J, Hirsh J, Hylek E et al. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Supl):160S-98S.
96. Hylek EM, Regan S, Go AS et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001 Sep 18;135(6):393-400.
97. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001 Oct; 86(4):980-4.
98. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007 Oct;24(2):93-7.
99. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet. 2000 Nov 4;356(9241):1551-3.
100. Lubetsky A, Yonath H, Olchovsky D, Loebstein R et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003 Nov 10;163(20):2469-73.
101. Ortel TL, Hasselblad V. A double blind randomized control trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism (PERIOP-2) [internet]. Canadian Institutes of Health Research (CIHR); 2011. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00432796?term=periop&rank=1.
102. Ortel TL, Hasselblad V .Effectiveness of bridging anticoagulation for surgery (The BRIDGE Study) [internet]. National Heart, Lung, and Blood Institute (NHLBI); 2009. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00786474?term=bridge&rank=26.

Vol. 53 Núm. 3 (2012)